Rhythm Pharma Q4 2025 IMCIVREE revenue ~$57M (+11% QoQ); FY2025 ~$194M (+50% YoY)

RHYTHM PHARMACEUTICALS, INC.

2025-FY EPS reported -$3.11 revenue$189,757,000

Q4 2025 net product revenue ~$57M, up 11% sequentially from Q3 2025.
FY2025 net product revenue ~$194M, a ~50% increase from $130M in FY2024.
U.S. sales contributed ~68% of Q4 and ~69% of full-year 2025 revenues.
FDA PDUFA goal date of March 20, 2026 for setmelanotide sNDA in acquired hypothalamic obesity.
Topline data from Phase 3 EMANATE trial in MC4R pathway diseases expected in Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.